Compass Pathways (NASDAQ:CMPS) Cut to Strong Sell at Wall Street Zen

Wall Street Zen lowered shares of Compass Pathways (NASDAQ:CMPS) from a sell rating to a strong sell rating in a report released on Saturday,Wall Street Zen reports.

Other research analysts also recently issued research reports about the stock. Wolfe Research reaffirmed an “outperform” rating on shares of Compass Pathways in a research report on Tuesday, July 7th. HC Wainwright decreased their target price on shares of Compass Pathways from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Pathways in a research note on Thursday, October 15th. Compass Point set a $25.00 target price on shares of Compass Pathways in a research note on Tuesday, July 7th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Compass Pathways in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.36.

Compass Pathways Price Performance

CMPS opened at $8.41 on Friday. The business’s 50-day moving average is $12.81 and its two-hundred day moving average is $10.39. Compass Pathways has a 1 year low of $4.88 and a 1 year high of $15.87. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.30 and a quick ratio of 1.30. The firm has a market capitalization of $1.16 billion, a PE ratio of -1.82 and a beta of 2.55.

Compass Pathways (NASDAQ:CMPS) last announced its earnings results on Wednesday, August 5th. The company reported ($1.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($1.49). Research analysts anticipate that Compass Pathways will post -1.26 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Pathways

A number of large investors have recently modified their holdings of the business. Vivo Capital LLC purchased a new position in shares of Compass Pathways in the first quarter worth $1,106,000. Seven Fleet Capital Management LP lifted its stake in shares of Compass Pathways by 295.1% during the first quarter. Seven Fleet Capital Management LP now owns 158,021 shares of the company’s stock worth $874,000 after buying an additional 118,021 shares during the period. Orbimed Advisors LLC acquired a new stake in shares of Compass Pathways during the first quarter worth $6,363,000. Eversept Partners LP purchased a new stake in shares of Compass Pathways during the first quarter valued at $3,749,000. Finally, Eagle Health Investments LP grew its holdings in shares of Compass Pathways by 35.6% during the first quarter. Eagle Health Investments LP now owns 2,060,427 shares of the company’s stock valued at $11,394,000 after buying an additional 541,039 shares during the last quarter. Hedge funds and other institutional investors own 46.19% of the company’s stock.

About Compass Pathways

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.